Cantargia obtains patent approval for the antibody CAN04 (nidanilimab) in Japan
Cantargia AB announce that the Japanese patent authority, JPO has formally approved the company’s patent application of the antibody CAN04 (nidanilimab). CAN04 binds interleukin 1 receptor accessory protein (IL1RAP), blocks its activity and the antibody is being developed for cancer therapy. The granted patent has number JP6396488.
Cantargia develops antibodies against IL1RAP for the treatment of life threating diseases. The main project, the immuno-oncology antibody CAN04, with a dual mechanism of action, is currently investigated in a phase I/IIa clinical trial focused on treatment of non-small cell lung cancer and pancreatic cancer. The patent application which now has been granted in Japan concerns the product candidate CAN04, as well as its use in cancer treatment. Cantargia has already corresponding patent protection in e.g. Europe, USA and China. The patent in Japan confers protection until 2035. Cantargia also has granted patents around IL1RAP as a target molecule for antibody-based cancer therapy.
”Besides USA and Europe, Japan is the biggest market for pharmaceuticals. The granted patent is of high importance in a future commercialization of CAN04 on this strategically important market”, says Göran Forsberg, CEO of Cantargia.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.30 CET on 19 September 2018.
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm First North Premier (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.